BRPI0813513A2 - Terapia específica e medicamento usando ligantes de integrina para tratamento de câncer - Google Patents
Terapia específica e medicamento usando ligantes de integrina para tratamento de câncerInfo
- Publication number
- BRPI0813513A2 BRPI0813513A2 BRPI0813513-4A2A BRPI0813513A BRPI0813513A2 BR PI0813513 A2 BRPI0813513 A2 BR PI0813513A2 BR PI0813513 A BRPI0813513 A BR PI0813513A BR PI0813513 A2 BRPI0813513 A2 BR PI0813513A2
- Authority
- BR
- Brazil
- Prior art keywords
- integrine
- links
- cancer treatment
- medicinal product
- specific therapy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07014070 | 2007-07-18 | ||
PCT/EP2008/005831 WO2009010287A2 (en) | 2007-07-18 | 2008-07-17 | Specific therapy and medicament using integrin ligands for treating cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0813513A2 true BRPI0813513A2 (pt) | 2015-01-06 |
Family
ID=39402737
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0806596-9A BRPI0806596A2 (pt) | 2007-01-18 | 2008-01-17 | medicamento e terapia especÍfica usando-se ligantes de integrina para o tratamento de cÂncer |
BRPI0813513-4A2A BRPI0813513A2 (pt) | 2007-07-18 | 2008-07-17 | Terapia específica e medicamento usando ligantes de integrina para tratamento de câncer |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0806596-9A BRPI0806596A2 (pt) | 2007-01-18 | 2008-01-17 | medicamento e terapia especÍfica usando-se ligantes de integrina para o tratamento de cÂncer |
Country Status (19)
Country | Link |
---|---|
US (2) | US20100069302A1 (pt) |
EP (4) | EP2101805B1 (pt) |
JP (3) | JP2010516645A (pt) |
KR (2) | KR20090108713A (pt) |
CN (2) | CN101588812A (pt) |
AU (2) | AU2008207095B2 (pt) |
BR (2) | BRPI0806596A2 (pt) |
CA (2) | CA2675813A1 (pt) |
CO (1) | CO6382135A2 (pt) |
DK (1) | DK2101805T3 (pt) |
EA (2) | EA017864B1 (pt) |
EC (1) | ECSP109969A (pt) |
ES (2) | ES2472450T3 (pt) |
IL (1) | IL199696A0 (pt) |
MX (1) | MX2009007597A (pt) |
PL (1) | PL2101805T3 (pt) |
PT (1) | PT2101805E (pt) |
WO (2) | WO2008087025A2 (pt) |
ZA (1) | ZA200905703B (pt) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20090108713A (ko) * | 2007-01-18 | 2009-10-16 | 메르크 파텐트 게엠베하 | 인테그린 리간드를 사용하는 암치료용 특이적 요법 및 의약 |
US20110230423A1 (en) * | 2008-11-20 | 2011-09-22 | Martin Andreas Picard | Therapy and medicament using integrin ligands for treating cancer |
JP2012528079A (ja) * | 2009-05-25 | 2012-11-12 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 癌を治療するためのインテグリンリガンドの連続投与 |
CA2775601C (en) | 2009-09-28 | 2017-10-03 | Qilu Pharmaceutical Co., Ltd | 4-(substituted anilino)-quinazoline derivatives useful as tyrosine kinase inhibitors |
WO2011146819A2 (en) * | 2010-05-20 | 2011-11-24 | Dmd Therapies, Llc | METHODS AND COMPOSITIONS FOR TREATMENT NF-κB-MEDIATED AND α7 INTEGRIN-SUPPRESSED DISEASES |
KR20150091504A (ko) * | 2012-12-07 | 2015-08-11 | 백스터 인터내셔널 인코포레이티드 | 항―mif 항체 세포 이동 검정법 |
US20160317531A1 (en) * | 2013-06-21 | 2016-11-03 | The General Hospital Corporation | Ribonucleotide reductase inhibitors sensitize tumor cells to dna damaging agents |
KR101579054B1 (ko) * | 2014-03-26 | 2015-12-21 | 한국원자력의학원 | 포도필로톡신 아세테이트를 유효 성분으로 포함하는 방사선치료 증진제 |
RU2017113001A (ru) * | 2014-09-17 | 2018-10-17 | Мерк Патент Гмбх | Способ лечения метастазов в кости, предназначенные для этого медикаменты, и способ прогнозирования клинического исхода лечения метастазов в кости |
EP3212210B1 (en) * | 2014-10-30 | 2019-12-11 | Big DNA Ltd | Combination therapy |
EP3207937A1 (en) | 2016-02-17 | 2017-08-23 | Royal College of Surgeons in Ireland | A method of treating or preventing sepsis |
CN105906692A (zh) * | 2016-03-11 | 2016-08-31 | 李书鹏 | cRGD-厄洛替尼缀合物及其制备方法 |
GB2554333A (en) * | 2016-04-26 | 2018-04-04 | Big Dna Ltd | Combination therapy |
WO2018145076A1 (en) * | 2017-02-06 | 2018-08-09 | Expression Pathology, Inc. | Quantifying mgmt protein for optimal cancer therapy |
JP2024512824A (ja) | 2021-01-22 | 2024-03-19 | ロイヤル カレッジ オブ サージャンズ イン アイルランド | コロナウイルスの治療 |
Family Cites Families (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US701446A (en) | 1901-12-30 | 1902-06-03 | Lewis W Wooten | Cotton-chopper. |
US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
US5260291A (en) | 1981-08-24 | 1993-11-09 | Cancer Research Campaign Technology Limited | Tetrazine derivatives |
US4589881A (en) | 1982-08-04 | 1986-05-20 | La Jolla Cancer Research Foundation | Polypeptide |
US4578079A (en) | 1982-08-04 | 1986-03-25 | La Jolla Cancer Research Foundation | Tetrapeptide |
US4614517A (en) | 1982-08-04 | 1986-09-30 | La Jolla Cancer Research Foundation | Tetrapeptide |
US4661111A (en) | 1982-08-04 | 1987-04-28 | La Jolla Cancer Research Foundation | Polypeptide |
US4517686A (en) | 1982-08-04 | 1985-05-21 | La Jolla Cancer Research Foundation | Polypeptide |
US4792525A (en) | 1982-08-04 | 1988-12-20 | La Jolla Cancer Research Foundation | Tetrapeptide |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
ATE144793T1 (de) | 1989-06-29 | 1996-11-15 | Medarex Inc | Bispezifische reagenzien für die aids-therapie |
WO1991003493A1 (en) | 1989-08-29 | 1991-03-21 | The University Of Southampton | Bi-or trispecific (fab)3 or (fab)4 conjugates |
CA2093022C (en) | 1990-10-05 | 2005-02-22 | Michael W. Fanger | Targeted immunostimulation with bispecific reagents |
WO1992010209A1 (en) | 1990-12-04 | 1992-06-25 | The Wistar Institute Of Anatomy And Biology | Bifunctional antibodies and method of preparing same |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
WO1993016185A2 (en) | 1992-02-06 | 1993-08-19 | Creative Biomolecules, Inc. | Biosynthetic binding protein for cancer marker |
US5407804A (en) | 1992-05-22 | 1995-04-18 | Applied Genetics Inc. | Assays for O6 -methylguanine-DNA methyltransferase |
GB9224888D0 (en) | 1992-11-27 | 1993-01-13 | Univ Singapore | Monoclonal antibody |
ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
US5753230A (en) | 1994-03-18 | 1998-05-19 | The Scripps Research Institute | Methods and compositions useful for inhibition of angiogenesis |
US5504101A (en) | 1994-05-06 | 1996-04-02 | Allelix Biopharmaceuticals, Inc. | 5-HT-1D receptor ligands |
US5741796A (en) | 1994-05-27 | 1998-04-21 | Merck & Co., Inc. | Pyridyl and naphthyridyl compounds for inhibiting osteoclast-mediated bone resorption |
EP0762882A4 (en) | 1994-06-29 | 2002-09-11 | Smithkline Beecham Corp | Vibronectin Receptor Antagonists |
EP0767792A4 (en) | 1994-06-29 | 2002-11-20 | Smithkline Beecham Corp | VITRONECTIN RECEPTOR ANTAGONISTS |
IT1271688B (it) | 1994-08-04 | 1997-06-04 | Menarini Ricerche Sud Spa | Molecole ibride per il trattamento antitumorale loro preparazione e loro uso in composizioni farmaceutiche |
ES2152412T3 (es) * | 1994-08-08 | 2001-02-01 | Debiopharm Sa | Preparacion farmaceuticamente estable de oxaliplatino. |
JPH10504825A (ja) | 1994-08-22 | 1998-05-12 | スミスクライン・ビーチャム・コーポレイション | 二環式化合物 |
WO1996026190A1 (en) | 1995-02-22 | 1996-08-29 | Smithkline Beecham Corporation | Integrin receptor antagonists |
US5780426A (en) | 1995-06-07 | 1998-07-14 | Ixsys, Incorporated | Fivemer cyclic peptide inhibitors of diseases involving αv β3 |
EP0910563B1 (en) | 1995-06-29 | 2003-05-02 | Smithkline Beecham Corporation | Integrin receptor antagonists |
DE19534177A1 (de) | 1995-09-15 | 1997-03-20 | Merck Patent Gmbh | Cyclische Adhäsionsinhibitoren |
CA2241633A1 (en) | 1995-12-29 | 1997-07-10 | William Henry Miller | Vitronectin receptor antagonists |
CA2241724A1 (en) | 1995-12-29 | 1997-07-10 | Smithkline Beecham Corporation | Vitronectin receptor antagonists |
TR199801254T2 (xx) | 1995-12-29 | 1998-10-21 | Smithkline Beecham Corporation | Vitronektin resept�r� antagonistleri. |
EA002271B1 (ru) | 1996-03-20 | 2002-02-28 | Хехст Марион Руссель | ТРИЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ, ОБЛАДАЮЩИЕ АКТИВНОСТЬЮ В ОТНОШЕНИИ ИНТЕГРИНОВ, В ЧАСТНОСТИ В ОТНОШЕНИИ ИНТЕГРИНА АЛЬФАvБЕТА 3, СПОСОБ ИХ ПОЛУЧЕНИЯ И ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ, ИСПОЛЬЗУЕМЫЕ В ЭТОМ СПОСОБЕ, ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ МЕДИКАМЕНТОВ И СОДЕРЖАЩИЕ ИХ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ |
JP2000508319A (ja) | 1996-04-10 | 2000-07-04 | メルク エンド カンパニー インコーポレーテッド | αvβ3拮抗薬 |
US5925655A (en) | 1996-04-10 | 1999-07-20 | Merck & Co., Inc. | αv β3 antagonists |
AU2438297A (en) | 1996-05-09 | 1997-11-26 | Alcon Laboratories, Inc. | Combinations of angiostatic compounds |
CA2256588A1 (en) * | 1996-05-31 | 1997-12-04 | The Scripps Research Institute | Methods and compositions useful for inhibition of .alpha.v.beta.5 mediated angiogenesis |
US5786146A (en) | 1996-06-03 | 1998-07-28 | The Johns Hopkins University School Of Medicine | Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids |
US6017704A (en) | 1996-06-03 | 2000-01-25 | The Johns Hopkins University School Of Medicine | Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids |
CA2263999A1 (en) | 1996-08-29 | 1998-03-05 | Merck & Co., Inc. | Integrin antagonists |
US5981546A (en) | 1996-08-29 | 1999-11-09 | Merck & Co., Inc. | Integrin antagonists |
JP2001501951A (ja) | 1996-10-07 | 2001-02-13 | スミスクライン・ビーチャム・コーポレイション | 骨形成刺激方法 |
WO1998018461A1 (en) | 1996-10-30 | 1998-05-07 | Merck & Co., Inc. | Integrin antagonists |
US5919792A (en) | 1996-10-30 | 1999-07-06 | Merck & Co., Inc. | Integrin antagonists |
WO1998018460A1 (en) | 1996-10-30 | 1998-05-07 | Merck & Co., Inc. | Integrin antagonists |
AU5596298A (en) | 1996-12-09 | 1998-07-03 | Cor Therapeutics, Inc. | Integrin antagonists |
DE19653647A1 (de) | 1996-12-20 | 1998-06-25 | Hoechst Ag | Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung |
DE19653645A1 (de) | 1996-12-20 | 1998-06-25 | Hoechst Ag | Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung |
DE19653646A1 (de) | 1996-12-20 | 1998-06-25 | Hoechst Ag | Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung |
CO4920232A1 (es) | 1997-01-08 | 2000-05-29 | Smithkline Beecham Corp | Acidos aceticos dibenzo [a,d] cicloheptano con actividad antagonista del receptor de vitronectin |
EP1007026A4 (en) | 1997-01-17 | 2002-08-07 | Merck & Co Inc | INTEGRIN ANTAGONISTS |
AU751659B2 (en) | 1997-05-02 | 2002-08-22 | Genentech Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
EP1000031A4 (en) | 1997-07-25 | 2001-08-16 | Smithkline Beecham Corp | VITRONECTIN RECEPTOR ANTAGONISTS |
CA2298544A1 (en) | 1997-08-04 | 1999-02-11 | Smithkline Beecham Corporation | Integrin receptor antagonists |
EP1027337A4 (en) | 1997-09-04 | 2002-04-03 | Smithkline Beecham Corp | Integrin receptor Antagonist |
PE122699A1 (es) | 1997-09-19 | 2000-02-12 | Smithkline Beecham Corp | Antagonistas de receptores de vitronectina |
PL339414A1 (en) | 1997-09-24 | 2000-12-18 | Smithkline Beecham Corp | Antagonistic vitronectin receptor |
FR2768734B1 (fr) | 1997-09-24 | 2000-01-28 | Roussel Uclaf | Nouveaux composes tricycliques, leur procede de preparation et les intermediaires de ce procede, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant |
FR2768736B1 (fr) | 1997-09-24 | 2000-05-26 | Roussel Uclaf | Nouveaux composes tricycliques, leur procede de preparation et les intermediaires de ce procede, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant |
CA2303846A1 (en) | 1997-09-24 | 1999-04-01 | Smithkline Beecham Corporation | Vitronectin receptor antagonist |
US6017926A (en) | 1997-12-17 | 2000-01-25 | Merck & Co., Inc. | Integrin receptor antagonists |
ATE294163T1 (de) | 1997-12-17 | 2005-05-15 | Merck & Co Inc | Integrin-rezeptor-antagonisten |
AU736026B2 (en) | 1997-12-17 | 2001-07-26 | Merck & Co., Inc. | Integrin receptor antagonists |
WO1999030713A1 (en) | 1997-12-17 | 1999-06-24 | Merck & Co., Inc. | Integrin receptor antagonists |
SK9162000A3 (en) | 1997-12-17 | 2001-03-12 | Merck & Co Inc | Integrin receptor antagonists |
US6048861A (en) | 1997-12-17 | 2000-04-11 | Merck & Co., Inc. | Integrin receptor antagonists |
CA2319160A1 (en) | 1998-01-23 | 1999-07-29 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Monoclonal antibody anti .alpha.v-integrin and its use to inhibit .alpha.v.beta.6-integrin attachment to fibronectin |
AU747784B2 (en) | 1998-07-29 | 2002-05-23 | Merck & Co., Inc. | Integrin receptor antagonists |
AU748621B2 (en) | 1998-08-13 | 2002-06-06 | Merck & Co., Inc. | Integrin receptor antagonists |
DE19842415A1 (de) | 1998-09-16 | 2000-03-23 | Merck Patent Gmbh | Pharmazeutische Zubereitung |
CA2356402A1 (en) * | 1998-12-23 | 2000-07-06 | G.D. Searle & Co. | Use of a matrix metalloproteinase inhibitor and an integrin antagonist in the treatment of neoplasia |
CZ20014308A3 (cs) | 1999-06-02 | 2002-03-13 | Merck And Co., Inc. | Deriváty kyseliny nonanové |
US7247619B2 (en) * | 2000-05-19 | 2007-07-24 | Univ Leland Stanford Junior | Viral vectors useful in induction of humoral or cellular immunity |
EP1328656A4 (en) * | 2000-09-29 | 2005-09-14 | Univ Johns Hopkins Med | METHOD FOR PREDICTING THE CLINICAL RESPONSE TO CHEMOTHERAPY WITH ALKYLATING AGENTS |
US20040052785A1 (en) * | 2001-01-09 | 2004-03-18 | Simon Goodman | Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors |
CN1247258C (zh) * | 2001-04-24 | 2006-03-29 | 默克专利有限公司 | 使用抗血管生成剂和TNFα的联合疗法 |
DE10228049A1 (de) * | 2002-06-24 | 2004-01-15 | Merck Patent Gmbh | Flüssige Zubereitung enthaltend Oligopeptide |
US20060084666A1 (en) * | 2004-10-18 | 2006-04-20 | Harari Paul M | Combined treatment with radiation and an epidermal growth factor receptor kinase inhibitor |
EP2335733B1 (en) * | 2006-01-18 | 2014-08-06 | Merck Patent GmbH | Specific therapy using integrin ligands for treating cancer |
KR20090108713A (ko) * | 2007-01-18 | 2009-10-16 | 메르크 파텐트 게엠베하 | 인테그린 리간드를 사용하는 암치료용 특이적 요법 및 의약 |
-
2008
- 2008-01-17 KR KR1020097017119A patent/KR20090108713A/ko not_active Application Discontinuation
- 2008-01-17 BR BRPI0806596-9A patent/BRPI0806596A2/pt not_active IP Right Cessation
- 2008-01-17 CA CA002675813A patent/CA2675813A1/en not_active Abandoned
- 2008-01-17 CN CNA2008800024456A patent/CN101588812A/zh active Pending
- 2008-01-17 EA EA200900912A patent/EA017864B1/ru not_active IP Right Cessation
- 2008-01-17 US US12/523,491 patent/US20100069302A1/en not_active Abandoned
- 2008-01-17 ES ES11009510.6T patent/ES2472450T3/es active Active
- 2008-01-17 ES ES08707093T patent/ES2399159T3/es active Active
- 2008-01-17 EP EP08707093A patent/EP2101805B1/en not_active Not-in-force
- 2008-01-17 DK DK08707093.4T patent/DK2101805T3/da active
- 2008-01-17 PT PT87070934T patent/PT2101805E/pt unknown
- 2008-01-17 WO PCT/EP2008/000328 patent/WO2008087025A2/en active Application Filing
- 2008-01-17 PL PL08707093T patent/PL2101805T3/pl unknown
- 2008-01-17 EP EP11009510.6A patent/EP2441464B1/en not_active Not-in-force
- 2008-01-17 MX MX2009007597A patent/MX2009007597A/es active IP Right Grant
- 2008-01-17 JP JP2009545872A patent/JP2010516645A/ja active Pending
- 2008-01-17 AU AU2008207095A patent/AU2008207095B2/en not_active Ceased
- 2008-07-17 JP JP2010516420A patent/JP2010533665A/ja active Pending
- 2008-07-17 AU AU2008277904A patent/AU2008277904A1/en not_active Abandoned
- 2008-07-17 CA CA2693862A patent/CA2693862A1/en not_active Abandoned
- 2008-07-17 US US12/668,823 patent/US20100190957A1/en not_active Abandoned
- 2008-07-17 EP EP12007334.1A patent/EP2578225A1/en not_active Withdrawn
- 2008-07-17 WO PCT/EP2008/005831 patent/WO2009010287A2/en active Application Filing
- 2008-07-17 KR KR1020107003515A patent/KR20100043242A/ko not_active Application Discontinuation
- 2008-07-17 EP EP08774010A patent/EP2164506A2/en not_active Ceased
- 2008-07-17 EA EA201000127A patent/EA201000127A1/ru unknown
- 2008-07-17 CN CN200880024802A patent/CN101743013A/zh active Pending
- 2008-07-17 BR BRPI0813513-4A2A patent/BRPI0813513A2/pt not_active IP Right Cessation
-
2009
- 2009-07-05 IL IL199696A patent/IL199696A0/en unknown
- 2009-08-17 ZA ZA200905703A patent/ZA200905703B/xx unknown
-
2010
- 2010-01-15 CO CO10003771A patent/CO6382135A2/es not_active Application Discontinuation
- 2010-02-17 EC EC2010009969A patent/ECSP109969A/es unknown
-
2013
- 2013-10-18 JP JP2013217677A patent/JP2014015482A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0813513A2 (pt) | Terapia específica e medicamento usando ligantes de integrina para tratamento de câncer | |
BRPI0821660A2 (pt) | Combinações de agentes terapêuticos para tratamento de câncer | |
BRPI0922771A2 (pt) | agentes indutores de apoptose seletivos para bcl-2 para o tratamento de câncer e doenças imunes | |
BRPI0810816A2 (pt) | Medicamento e métodos para tratar doenças auto-imune e câncer | |
BRPI0821779A2 (pt) | tratamento terapêutico de câncer | |
BRPI0811589A2 (pt) | Composição farmacêutica e método para tratar câncer | |
BR112012018947A2 (pt) | composição farmacêutica para tratamento e\ou prevenção do cancêr | |
DK2121139T3 (da) | Formulations for cancer treatment | |
EP2166837A4 (en) | DRUG COMBINATION USEFUL FOR THE TREATMENT OF SKIN DISORDERS | |
BRPI0807987A2 (pt) | Terapia de combinação para tratamento de distúrbios imunes. | |
EP2165715A4 (en) | THERAPEUTIC AGENT FOR CANCER AND METHOD FOR TREATING CANCER | |
EP2046973A4 (en) | METHODS OF IDENTIFYING, EVALUATING, AND TREATING PATIENTS SUBJECTED TO ANTICANCER THERAPY | |
BRPI0816712A2 (pt) | terapia de intervalo para o tratamento de tinnitus | |
EP2125002A4 (en) | TREATMENT OF SKIN CANCER | |
BRPI0821248A2 (pt) | Inibidores de cinesina como fármacos terapêuticos para câncer | |
IL201460A0 (en) | Phthalazinone derivatives and their use as medicament to treat cancer | |
IL205608A (en) | History of s-triazole-1-ram-benzamide and their use in the preparation of pain medication | |
BRPI0820477A2 (pt) | Compostos de benzodiazepinona úteis no tratamento de afecções da pele | |
EP2219448A4 (en) | THERAPEUTIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF DISEASES AND SUFFERINGS | |
BR112012031836A2 (pt) | combinação farmacêutica para o tratamento da dor | |
IL206173A0 (en) | 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases | |
EP2148675A4 (en) | ANTI-CANCER FOR THE DIAGNOSIS AND TREATMENT OF CANCER | |
BRPI1010086A2 (pt) | método e produtos para tratamento de doenças | |
BRPI1009448A2 (pt) | combinações farmacêuticas compreendendo edea119/bay 869766 para o tratamento de cânceres específicos | |
BRPI0922367A2 (pt) | enzastaurin para o tratamento de câncer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 6A E 7A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |